LivaNova (LIVN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

LivaNova Revenue Highlights

Latest Revenue (Y)

$1.25B

Latest Revenue (Q)

$357.80M

Main Segment (Y)

Cardiopulmonary Segment

Main Geography (Y)

UNITED STATES

LivaNova Revenue by Period

LivaNova Revenue by Year

Date	Revenue	Change
2024-12-31	$1.25B	8.66%
2023-12-31	$1.15B	12.89%
2022-12-31	$1.02B	-1.31%
2021-12-31	$1.04B	10.83%
2020-12-31	$934.20M	-13.84%
2019-12-31	$1.08B	-2.06%
2018-12-31	$1.11B	9.35%
2017-12-31	$1.01B	-16.61%
2016-12-31	$1.21B	316.35%
2015-04-30	$291.56M	3.38%
2014-04-30	$282.01M	10.89%
2013-04-30	$254.32M	16.39%
2012-04-30	$218.50M	14.72%
2011-04-30	$190.46M	13.52%
2010-04-30	$167.78M	16.83%
2009-04-30	$143.60M	18.45%
2008-04-30	$121.23M	-7.44%
2007-04-30	$130.97M	6.10%
2006-04-30	$123.44M	19.33%
2005-04-30	$103.44M	-6.57%
2004-04-30	$110.72M	5.99%
2003-04-30	$104.47M	49.00%
2002-04-30	$70.11M	46.40%
2000-06-30	$47.89M	60.16%
1999-06-30	$29.90M	100.67%
1998-06-30	$14.90M	964.29%
1997-06-30	$1.40M	-
1996-06-30	$1.40M	40.00%
1995-06-30	$1.00M	150.00%
1994-06-30	$400.00K	300.00%
1993-06-30	$100.00K	-

LivaNova generated $1.25B in revenue during NA 2024, up 8.66% compared to the previous quarter, and up 115.61% compared to the same period a year ago.

LivaNova Revenue by Quarter

Date	Revenue	Change
2025-09-30	$357.80M	1.50%
2025-06-30	$352.52M	11.26%
2025-03-31	$316.86M	-1.54%
2024-12-31	$321.80M	1.16%
2024-09-30	$318.12M	-0.14%
2024-06-30	$318.57M	8.02%
2024-03-31	$294.91M	-4.90%
2023-12-31	$310.10M	8.39%
2023-09-30	$286.10M	-2.65%
2023-06-30	$293.90M	11.58%
2023-03-31	$263.40M	-4.18%
2022-12-31	$274.90M	8.83%
2022-09-30	$252.60M	-0.63%
2022-06-30	$254.20M	5.84%
2022-03-31	$240.18M	-11.08%
2021-12-31	$270.10M	6.67%
2021-09-30	$253.22M	-4.26%
2021-06-30	$264.48M	6.82%
2021-03-31	$247.60M	-8.16%
2020-12-31	$269.60M	12.29%
2020-09-30	$240.08M	31.76%
2020-06-30	$182.21M	-24.83%
2020-03-31	$242.40M	-15.72%
2019-12-31	$287.60M	7.07%
2019-09-30	$268.61M	-3.09%
2019-06-30	$277.17M	10.51%
2019-03-31	$250.80M	-15.56%
2018-12-31	$297.00M	9.16%
2018-09-30	$272.08M	-5.36%
2018-06-30	$287.50M	14.82%
2018-03-31	$250.40M	-10.06%
2017-12-31	$278.40M	-10.10%
2017-09-30	$309.66M	-3.65%
2017-06-30	$321.39M	12.73%
2017-03-31	$285.11M	-8.21%
2016-12-31	$310.60M	5.19%
2016-09-30	$295.27M	-8.02%
2016-06-30	$321.00M	11.85%
2016-03-31	$287.00M	325.05%
2015-10-18	$67.52M	-16.65%
2015-07-31	$81.01M	9.37%
2015-04-30	$74.07M	2.78%
2015-01-31	$72.07M	-1.84%
2014-10-31	$73.42M	1.96%
2014-07-31	$72.00M	-3.80%
2014-04-30	$74.85M	9.76%
2014-01-31	$68.19M	-2.72%
2013-10-31	$70.10M	1.78%
2013-07-31	$68.87M	0.77%
2013-04-30	$68.34M	9.00%
2013-01-31	$62.70M	-0.41%
2012-10-31	$62.96M	4.37%
2012-07-31	$60.32M	4.71%
2012-04-30	$57.61M	5.63%
2012-01-31	$54.54M	1.57%
2011-10-31	$53.70M	1.96%
2011-07-31	$52.66M	3.01%
2011-04-30	$51.12M	8.58%
2011-01-31	$47.08M	-0.80%
2010-10-31	$47.46M	5.94%
2010-07-31	$44.80M	-6.15%
2010-04-30	$47.73M	16.94%
2010-01-31	$40.82M	0.25%
2009-10-31	$40.72M	5.76%
2009-07-31	$38.50M	-0.20%
2009-04-30	$38.58M	9.41%
2009-01-31	$35.26M	-2.14%
2008-10-31	$36.03M	6.82%
2008-07-31	$33.73M	-0.47%
2008-04-30	$33.89M	7.83%
2007-04-30	$31.43M	-7.93%
2006-10-31	$34.14M	1.21%
2006-07-31	$33.73M	-6.43%
2006-04-30	$36.05M	24.00%
2005-10-31	$29.07M	7.59%
2005-07-31	$27.02M	1.35%
2005-04-30	$26.66M	-

LivaNova generated $357.80M in revenue during Q3 2025, up 1.50% compared to the previous quarter, and up 112.31% compared to the same period a year ago.

LivaNova Revenue Breakdown

LivaNova Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Cardiopulmonary Segment	$683.51M	$588.98M	$500.31M	$482.98M	-
Neuromodulation Segment	$554.22M	$519.71M	$476.99M	$456.17M	$354.44M
Advanced Circulatory Support Segment	-	$40.32M	$39.30M	$55.46M	-
Cardiovascular Segment	-	-	-	-	$577.08M

LivaNova's latest annual revenue breakdown by segment (product or service), as of Dec 24: Cardiopulmonary Segment (55.22%), and Neuromodulation Segment (44.78%).

Quarterly Revenue by Product

Product/Service	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Cardiopulmonary Segment	$203.22M	$199.27M	$176.32M	$181.67M	$172.24M	$173.71M	$155.89M	$161.47M	$144.83M	$150.60M	$132.07M	$136.46M	$120.96M	$125.82M	$117.08M	-	-	-	-	-
Neuromodulation Segment	$149.53M	$151.67M	$138.89M	$137.61M	$139.86M	$142.88M	$133.87M	$136.93M	$128.88M	$133.18M	$120.72M	$127.14M	$121.83M	$117.80M	$110.23M	$121.55M	$113.29M	$117.64M	$103.70M	$109.17M
Advanced Circulatory Support Segment	-	-	-	-	-	-	-	$10.11M	$10.95M	$9.42M	$9.84M	$9.63M	$8.64M	$9.35M	$11.68M	-	-	-	-	-
Cardiovascular Segment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$138.63M	$145.88M	$143.17M	$159.60M

LivaNova's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Cardiopulmonary Segment (57.61%), and Neuromodulation Segment (42.39%).

LivaNova Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Europe	$220.03M	$214.79M	$178.80M	$201.53M	$193.37M
Locations Excluding The United States And Europe	$338.32M	$303.71M	$271.44M	$262.54M	$272.24M
UNITED STATES	$695.08M	$635.04M	$571.56M	$571.30M	$468.63M

LivaNova's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (55.45%), Locations Excluding The United States And Europe (26.99%), and Europe (17.55%).

Quarterly Revenue by Country

Country	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Locations Excluding The United States And Europe	$99.62M	$97.27M	$87.99M	$85.11M	$85.48M	$87.78M	$79.95M	$74.35M	$76.40M	$79.45M	$73.51M	$74.78M	$69.20M	$68.69M	$58.78M	$71.29M	$50.24M	$6.39M	$10.45M	$76.79M
Europe	$67.68M	$66.78M	$59.70M	$61.62M	$52.81M	$51.26M	$54.34M	$62.56M	$48.13M	$54.46M	$49.64M	$46.31M	$40.00M	$47.37M	$45.13M	$48.95M	$32.85M	$6.12M	$8.28M	$54.76M
UNITED STATES	$190.45M	$188.47M	$169.16M	$175.10M	$179.83M	$179.54M	$160.62M	$173.22M	$161.58M	$159.97M	$140.27M	$153.79M	$143.41M	$138.09M	$136.27M	$149.83M	$40.14M	$2.21M	$2.72M	$138.00M

LivaNova's latest quarterly revenue breakdown by geography, as of Sep 25: UNITED STATES (53.23%), Locations Excluding The United States And Europe (27.85%), and Europe (18.92%).

LivaNova Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
SGRY	Surgery Partners	$3.11B	$821.50M
LIVN	LivaNova	$1.25B	$357.80M
PBH	Prestige Consumer Healthcare	$1.13B	$274.11M
ATEC	Alphatec	$424.26M	-
ZLAB	Zai Lab	$398.99M	$116.09M
LEGN	Legend Biotech	$285.14M	$93.99M
HTFL	Heartflow	$125.81M	$46.27M
IDYA	IDEAYA Biosciences	$7.00M	$207.83M
CDTX	Cidara Therapeutics	$1.27M	-
IRON	Disc Medicine	-	$7.91M
SRRK	Scholar Rock	-	-

LIVN Revenue FAQ

What is LivaNova’s yearly revenue?

LivaNova's yearly revenue for 2024 was $1.25B, representing an increase of 8.66% compared to 2023. The company's yearly revenue for 2023 was $1.15B, representing an increase of 12.89% compared to 2022. LIVN's yearly revenue for 2022 was $1.02B, representing a decrease of -1.31% compared to 2021.

What is LivaNova’s quarterly revenue?

LivaNova's quarterly revenue for Q3 2025 was $357.8M, a 1.50% increase from the previous quarter (Q2 2025), and a 12.47% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $352.52M, a 11.26% increase from the previous quarter (Q1 2025), and a 10.66% increase year-over-year (Q2 2024). LIVN's quarterly revenue for Q1 2025 was $316.86M, a -1.54% decrease from the previous quarter (Q4 2024), and a 7.44% increase year-over-year (Q1 2024).

What is LivaNova’s revenue growth rate?

LivaNova's revenue growth rate for the last 3 years (2022-2024) was 22.67%, and for the last 5 years (2020-2024) was 34.17%.

What are LivaNova’s revenue streams?

LivaNova's revenue streams in c 24 are Cardiopulmonary Segment, and Neuromodulation Segment. Cardiopulmonary Segment generated $683.51M in revenue, accounting 55.22% of the company's total revenue, up 16.05% year-over-year. Neuromodulation Segment generated $554.22M in revenue, accounting 44.78% of the company's total revenue, up 6.64% year-over-year.

What is LivaNova’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of LivaNova was Cardiopulmonary Segment. This segment made a revenue of $683.51M, representing 55.22% of the company's total revenue.